Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manuela S Murgueitio

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Clinical & Developmental Immunology|January 15, 2011
Theoretical modeling techniques and their impact on tumor immunologyAnna Lena Woelke, Manuela S Murgueitio, Robert Preissner
Pharmacological Research|January 23, 2016
Acute myeloid leukaemia-derived Langerhans-like cells enhance Th1 polarization upon TLR2 engagementStephanie Bock, Manuela S Murgueitio, Gerhard Wolber, et al.
Trends in Pharmacological Sciences|November 20, 2016
Balancing Inflammation: Computational Design of Small-Molecule Toll-like Receptor ModulatorsManuela S Murgueitio, Christin Rakers, Anne Frank, et al.
Drug Discovery Today. Technologies|July 4, 2014
In silico virtual screening approaches for anti-viral drug discoveryManuela S Murgueitio, Marcel Bermudez, Jérémie Mortier, et al.
Biochemical Pharmacology|November 4, 2019
The novel small-molecule antagonist MMG-11 preferentially inhibits TLR2/1 signalingMaria Grabowski, Manuela S Murgueitio, Marcel Bermudez, et al.
Chemmedchem|January 29, 2014
Prospective virtual screening in a sparse data scenario: design of small-molecule TLR2 antagonistsManuela S Murgueitio, Philipp Henneke, Hartmut Glossmann, et al.
European Journal of Medicinal Chemistry|July 9, 2019
Identification and characterization of a novel chemotype for human TLR8 inhibitorsDora Šribar, Maria Grabowski, Manuela S Murgueitio, et al.
Biochemical Pharmacology|April 24, 2018
Identification of a pyrogallol derivative as a potent and selective human TLR2 antagonist by structure-based virtual screeningMaria Grabowski, Manuela S Murgueitio, Marcel Bermudez, et al.
Drug Discovery Today|January 24, 2015
The impact of molecular dynamics on drug design: applications for the characterization of ligand-macromolecule complexesJérémie Mortier, Christin Rakers, Marcel Bermudez, et al.
European Journal of Medicinal Chemistry|August 30, 2016
New telmisartan-derived PPARγ agonists: Impact of the 3D-binding mode on the pharmacological profileVictoria Obermoser, Margarethe E Urban, Manuela S Murgueitio, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Clinical & Developmental Immunology|January 15, 2011
Theoretical modeling techniques and their impact on tumor immunologyAnna Lena Woelke, Manuela S Murgueitio, Robert Preissner
Pharmacological Research|January 23, 2016
Acute myeloid leukaemia-derived Langerhans-like cells enhance Th1 polarization upon TLR2 engagementStephanie Bock, Manuela S Murgueitio, Gerhard Wolber, et al.
Trends in Pharmacological Sciences|November 20, 2016
Balancing Inflammation: Computational Design of Small-Molecule Toll-like Receptor ModulatorsManuela S Murgueitio, Christin Rakers, Anne Frank, et al.
Drug Discovery Today. Technologies|July 4, 2014
In silico virtual screening approaches for anti-viral drug discoveryManuela S Murgueitio, Marcel Bermudez, Jérémie Mortier, et al.
Biochemical Pharmacology|November 4, 2019
The novel small-molecule antagonist MMG-11 preferentially inhibits TLR2/1 signalingMaria Grabowski, Manuela S Murgueitio, Marcel Bermudez, et al.
Chemmedchem|January 29, 2014
Prospective virtual screening in a sparse data scenario: design of small-molecule TLR2 antagonistsManuela S Murgueitio, Philipp Henneke, Hartmut Glossmann, et al.
European Journal of Medicinal Chemistry|July 9, 2019
Identification and characterization of a novel chemotype for human TLR8 inhibitorsDora Šribar, Maria Grabowski, Manuela S Murgueitio, et al.
Biochemical Pharmacology|April 24, 2018
Identification of a pyrogallol derivative as a potent and selective human TLR2 antagonist by structure-based virtual screeningMaria Grabowski, Manuela S Murgueitio, Marcel Bermudez, et al.
Drug Discovery Today|January 24, 2015
The impact of molecular dynamics on drug design: applications for the characterization of ligand-macromolecule complexesJérémie Mortier, Christin Rakers, Marcel Bermudez, et al.
European Journal of Medicinal Chemistry|August 30, 2016
New telmisartan-derived PPARγ agonists: Impact of the 3D-binding mode on the pharmacological profileVictoria Obermoser, Margarethe E Urban, Manuela S Murgueitio, et al.
Pageof 2